These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30205040)

  • 1. Targeting the Residual Leukemia Cells after Chemotherapy.
    Vu LP; Kharas MG
    Cancer Cell; 2018 Sep; 34(3):353-355. PubMed ID: 30205040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence.
    Boyd AL; Aslostovar L; Reid J; Ye W; Tanasijevic B; Porras DP; Shapovalova Z; Almakadi M; Foley R; Leber B; Xenocostas A; Bhatia M
    Cancer Cell; 2018 Sep; 34(3):483-498.e5. PubMed ID: 30205048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.
    Bruserud Ø; Aasebø E; Hernandez-Valladares M; Tsykunova G; Reikvam H
    Expert Opin Drug Discov; 2017 Oct; 12(10):1053-1065. PubMed ID: 28748730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should minimal residual disease guide therapy in AML?
    Paietta E
    Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies for relapse control in acute myeloid leukemia.
    Martner A; Thorén FB; Aurelius J; Hellstrand K
    Blood Rev; 2013 Sep; 27(5):209-16. PubMed ID: 23871358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome and efficacy of current anti-leukemic therapy for leptomeningeal involvement in acute myeloid leukemia.
    Kwon JH; Koh YI; Yoon SS; Park S; Kim I
    Int J Hematol; 2016 Nov; 104(5):574-581. PubMed ID: 27431487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML evolution from preleukemia to leukemia and relapse.
    Shlush LI; Mitchell A
    Best Pract Res Clin Haematol; 2015; 28(2-3):81-9. PubMed ID: 26590763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
    Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
    J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
    Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
    Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
    Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
    Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
    Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
    Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.
    Bai Y; Zheng JE; Wang N; Cai HH; Zhai LN; Wu YH; Wang F; Jin RM; Zhou DF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):689-693. PubMed ID: 26489623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGFR2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy.
    Nóbrega-Pereira S; Caiado F; Carvalho T; Matias I; Graça G; Gonçalves LG; Silva-Santos B; Norell H; Dias S
    Cancer Res; 2018 Feb; 78(3):731-741. PubMed ID: 29229602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.
    van den Ancker W; van Luijn MM; Chamuleau ME; Kelder A; Feller N; Terwijn M; Zevenbergen A; Schuurhuis GJ; van Ham SM; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Leuk Res; 2014 Jun; 38(6):691-3. PubMed ID: 24731748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemic hypopyon in acute myeloid leukemia.
    Alten F; Ehlert K; Böhm MR; Grenzebach UH
    Eur J Ophthalmol; 2013; 23(2):252-4. PubMed ID: 23225088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.